title: Improvements in Immune Function and Activation with 48-Week Darunavir/Ritonavir-Based Therapy: GRACE Substudy.
abstract: Objective. During the course of HIV infection, progressive immune deficiency occurs. The aim of this prospective substudy was to evaluate the recovery of functional immunity in a subset of patients from the GRACE (Gender, Race, And Clinical Experience) study treated with a DRV/r-based regimen. Methods. The recovery of functional immunity with a darunavir/ritonavir-based regimen was assessed in a subset of treatment-experienced, HIV-1 infected patients from the GRACE study. Results. 19/32 patients (59%) enrolled in the substudy were virologically suppressed (<50 copies/mL). In these patients, median (range) CD4+ cell count increased from 222 (2, 398) cells/mm(3) at baseline to 398 (119, 812) cells/mm(3) at Week 48. CD8+% decreased significantly from baseline to Week 48 (P = .03). Proliferation of CD4+ lymphocytes in response to CD3+/CD28+, phytohemagglutinin, and pokeweed was significantly increased (P < .01) by Week 12. Proliferation in response to Candida and tetanus was significantly increased by Week 48 (P < .01 and P = .014, resp.). Staphylococcal enterotoxin B-stimulated tumor necrosis factor-alpha and interleukin-2 in CD4+ cells was significantly increased by Week 12 (P = .046) and Week 48 (P < .01), respectively. Conclusions. Darunavir/ritonavir-based therapy demonstrated improvements in CD4+ cell recovery and association with progressive functional immune recovery over 48 weeks. This trial is registered with NCT00381303.
authors.affiliation: Department of Microbiology and Immunology, McGill University Health Centre, Room A5-140, 1650 Cedar Avenue, Montreal, QC, Canada H3G 1A4.
authors.forename: Christos
authors.initials: C
authors.lastname: Tsoukas
authors.affiliation: Montreal General Hospital, Flowcytometry Laboratory, 1650 Cedar Avenue, Room C10-166, Montreal, QC, Canada H3G 1A4.
authors.forename: Louise
authors.initials: L
authors.lastname: Gilbert
authors.affiliation: Department of Microbiology and Immunology, McGill University Health Centre, Room A5-140, 1650 Cedar Avenue, Montreal, QC, Canada H3G 1A4.
authors.forename: Trevor
authors.initials: T
authors.lastname: Lewis
authors.affiliation: LAC+USC Medical Center, 1200 N State Street, Room IPT-C4E100, Los Angeles, CA 90033, USA.
authors.forename: George
authors.initials: G
authors.lastname: Hatzakis
authors.affiliation: Janssen Services, LLC, Clinical Affairs, 1125 Trenton-Harbourton Road, Titusville, NJ 08560, USA.
authors.forename: Ron
authors.initials: R
authors.lastname: Falcon
authors.affiliation: Janssen Services, LLC, Clinical Affairs, 1125 Trenton-Harbourton Road, Titusville, NJ 08560, USA.
authors.forename: Joseph
authors.initials: J
authors.lastname: Mrus